Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Normal saline + AT refers to a clinical formulation consisting of **antithrombin III (ATIII)** diluted in **0.9% sodium chloride (normal saline)**. Antithrombin III is a non-vitamin K-dependent protease inhibitor that inactivates thrombin and other activated coagulation factors (Factors IXa, Xa, XIa, and XIIa), thereby exerting a potent anticoagulant effect. In clinical practice, this combination is frequently utilized as a therapeutic intervention or a control arm in clinical trials investigating treatments for conditions characterized by coagulopathy, such as **sepsis-associated disseminated intravascular coagulation (DIC)**, hereditary antithrombin deficiency, and acute respiratory distress syndrome (ARDS). The saline serves as a vehicle for intravenous infusion, maintaining isotonicity and facilitating the systemic delivery of the antithrombin protein to restore physiological anticoagulant levels and mitigate microvascular thrombosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antithrombin iii + sodium chloride.